Beaumont Health - Grosse Pointe
- Type
- Teaching hospital
- Where
- Grosse Pointe, MI
- Medicare CCN
- 230089
- Received
- $1,524,211 in 282 records, 2025 ($209,719 general, $1,314,491 research)
- Source
- CMS Open Payments search ↗
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2025 | General payment | 59 | $209,719 |
| 2025 | Research payment | 223 | $1,314,491 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 223 | $1,314,491 |
| Long term medical supply or device loan | 13 | $84,940 |
| Space rental or facility fees (teaching hospital only) | 20 | $60,643 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 11 | $33,460 |
| Grant | 10 | $21,450 |
| Consulting Fee | 2 | $4,722 |
| Debt forgiveness | 3 | $4,503 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2025-12-31 | AngioDynamics, Inc. | $60,000 | Long term medical supply or device loan | In-kind items and services | NanoKnife Device, Oncology Surgery | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,808 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,716 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,716 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $3,716 | Long term medical supply or device loan | In-kind items and services | NA Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $2,861 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Teleflex LLC | $2,640 | Long term medical supply or device loan | Cash or cash equivalent | DEKNATEL Device, SURGICAL | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,860 | Long term medical supply or device loan | In-kind items and services | STRYKER Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Stryker Corporation | $1,767 | Long term medical supply or device loan | In-kind items and services | RemB Device, INSTRUMENTS | 2025 | |
| 2025-12-31 | Fisher & Paykel Healthcare Inc | $289 | Long term medical supply or device loan | In-kind items and services | FISHER & PAYKEL HEALTHCARE Device, Heated respiratory humidifier | 2025 | |
| 2025-12-30 | Imperative Care, Inc | $10,400 | Research payment | Cash or cash equivalent | SYMPHONY CATHETER Device, VASCULAR | THE IMPERATIVE TRIAL: TREATMENT OF ACUTE ISCHEMIC STROKE WITH THE ZOOM REPERFUSION SYSTEM | 2025 |
| 2025-12-30 | PFIZER INC. | $10,370 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,785 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $3,253 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,641 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-12-24 | United Therapeutics Corporation | $1,641 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-12-23 | Intuitive Surgical Operations, Inc. | $15,288 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | A prospective multicenter randomized control trial of da Vinci SP Surgical System vs Open Surgery in Nipple Sparing Mast | 2025 |
| 2025-12-17 | United Therapeutics Corporation | $8,561 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-12-17 | PFIZER INC. | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-12-17 | United Therapeutics Corporation | $1,552 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-12-17 | Janssen Research & Development, LLC | $1,435 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-12-17 | Novartis Pharmaceuticals Corporation | $81 | Research payment | In-kind items and services | A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [ | 2025 | |
| 2025-12-12 | Boston Scientific Corporation | $70,200 | Research payment | Cash or cash equivalent | Ablacath Catheter Device, Resolve-AF Clinical Trial | RESOLVE AF | 2025 |
| 2025-12-11 | Boston Scientific Corporation | $500 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-12-10 | United Therapeutics Corporation | $6,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-12-08 | PFIZER INC. | $1,400 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-12-08 | Biosense Webster, Inc. | $1,050 | Research payment | Cash or cash equivalent | Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla | 2025 | |
| 2025-12-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,608 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-12-01 | Stryker Corporation | $3,796 | Research payment | Cash or cash equivalent | GAMMA Device, TRAUMA & EXTREMETIES | POST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-2022 | 2025 |
| 2025-12-01 | Janssen Research & Development, LLC | $125 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-11-28 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Tachy Device, General - Tachy_CRM | 2025 | |
| 2025-11-27 | PFIZER INC. | $5,881 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $9,554 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $1,468 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-26 | United Therapeutics Corporation | $1,468 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-25 | Boston Scientific Corporation | $1,310 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-11-20 | Alnylam Pharmaceuticals Inc. | $15,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-11-20 | PFIZER INC. | $3,932 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-11-20 | KLS-Martin L.P. | $1,033 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE NEURO, MESH, SPECIALTY, TEMPORAL, 3D GRID, NEURO SCREW, 63 MM, T=0.6 MM, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-11-17 | UCB, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-17 | BridgeBio Pharma, Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-11-15 | Novartis Pharmaceuticals Corporation | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | LEQVIO Drug, Cardiology/Vascular Diseases | 2025 | |
| 2025-11-14 | SI-BONE, INC. | $340 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2025 |
| 2025-11-13 | KLS-Martin L.P. | $1,033 | Debt forgiveness | Cash or cash equivalent | LEVEL ONE NEURO, MESH, SPECIALTY, TEMPORAL, 3D GRID, NEURO SCREW, 63 MM, T=0.6 MM, CP TITANIUM, QTY: 001 EA Device, Osteosynthesis | 2025 | |
| 2025-11-12 | United Therapeutics Corporation | $8,380 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $4,838 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-11-12 | United Therapeutics Corporation | $4,190 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-11-10 | Biosense Webster, Inc. | $7,249 | Research payment | Cash or cash equivalent | Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation with the BWI PFA Pulsed Field Abla | 2025 | |
| 2025-11-03 | United Therapeutics Corporation | $7,344 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-11-01 | PFIZER INC. | $5,044 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-30 | SI-BONE, INC. | $5,602 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2025 |
| 2025-10-30 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-10-28 | Boehringer Ingelheim Pharmaceuticals, Inc. | $11,577 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-28 | Boston Scientific Corporation | $1,050 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-10-27 | Janssen Research & Development, LLC | $125 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-10-24 | Intuitive Surgical Operations, Inc. | $11,725 | Research payment | Cash or cash equivalent | Da Vinci Surgical System Device, SURGERY | A prospective multicenter randomized control trial of da Vinci SP Surgical System vs Open Surgery in Nipple Sparing Mast | 2025 |
| 2025-10-22 | United Therapeutics Corporation | $6,507 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-10-22 | Abbott Laboratories | $1,175 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ARCHITECT Device, Core Diagnostics | 2025 | |
| 2025-10-21 | Becton, Dickinson and Company | $16,667 | Research payment | Cash or cash equivalent | Midline catheter-related thrombosis | 2025 | |
| 2025-10-21 | KARL STORZ Endoscopy-America | $1,000 | Grant | Cash or cash equivalent | 2025 | ||
| 2025-10-20 | Janssen Research & Development, LLC | $1,395 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-10-17 | National Marrow Donor Program | $3,980 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-10-17 | Stryker Corporation | $615 | Research payment | Cash or cash equivalent | GAMMA Device, TRAUMA & EXTREMETIES | POST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-2022 | 2025 |
| 2025-10-15 | BridgeBio Pharma, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-15 | ModernaTX, Inc. | $1,628 | Research payment | Cash or cash equivalent | Comparing outcomes in COVID-19, RSV, and Influenza infections | 2025 | |
| 2025-10-15 | BridgeBio Pharma, Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-10-14 | PFIZER INC. | $5,051 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-10-13 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,458 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-10-03 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,339 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $25,844 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,187 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-10-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $3,792 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-29 | Janssen Research & Development, LLC | $1,375 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-09-26 | VB Spine LLC | $28,387 | Research payment | Cash or cash equivalent | TRITANIUM PL Device, Spine | Anterior Cervical Disectomy And Fusion Using The Tritanium C Anterior Cervical Cage For One Or Two-Levels (VB Spine) | 2025 |
| 2025-09-25 | PFIZER INC. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-09-23 | Neurocrine BioSciences, Inc. | $1,250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | INGREZZA Drug, Neuropsychiatry | 2025 | |
| 2025-09-19 | Janssen Research & Development, LLC | $5,010 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-09-19 | Ipsen Pharma SAS | $2,000 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-09-16 | Boston Scientific Corporation | $200 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-09-10 | United Therapeutics Corporation | $2,003 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | $7,854 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-05 | Janssen Research & Development, LLC | $272 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-09-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $44,302 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-09-04 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-09-04 | PFIZER INC. | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-09-04 | Janssen Research & Development, LLC | $1,375 | Research payment | Cash or cash equivalent | A Phase 3 Prospective Multi Center Double blind Double dummy Randomized Active controlled Parallel Group sequential Adap | 2025 | |
| 2025-09-03 | Abbott Laboratories | $1,275 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ARCHITECT Device, Core Diagnostics | 2025 | |
| 2025-09-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-08-30 | PFIZER INC. | $9,525 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-08-27 | United Therapeutics Corporation | $4,006 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-08-27 | United Therapeutics Corporation | $2,801 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-08-27 | PFIZER INC. | $1,666 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-08-26 | Boston Scientific Corporation | $1,390 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-08-26 | Merck Sharp & Dohme LLC | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | VERQUVO Drug, CARDIOVASCULAR | 2025 | |
| 2025-08-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | $12,499 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-08-21 | IRONWOOD PHARMACEUTICALS, INC | $793 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-08-20 | Janssen Research & Development, LLC | $4,970 | Research payment | Cash or cash equivalent | A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STR | 2025 | |
| 2025-08-19 | IRONWOOD PHARMACEUTICALS, INC | $297 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-08-13 | ModernaTX, Inc. | $95,556 | Research payment | Cash or cash equivalent | Comparing outcomes in COVID-19, RSV, and Influenza infections | 2025 | |
| 2025-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $14,200 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-11 | Boehringer Ingelheim Pharmaceuticals, Inc. | $250 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2025 | ||
| 2025-08-09 | PFIZER INC. | $5,044 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-08-08 | Ipsen Pharma SAS | $1,989 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-08-08 | Ipsen Pharma SAS | $1,881 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-08-06 | GE HEALTHCARE | $2,361 | Consulting Fee | Cash or cash equivalent | 2025 | ||
| 2025-08-04 | Boehringer Ingelheim Pharmaceuticals, Inc. | $21,331 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-08-04 | PFIZER INC. | $4,159 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-07-29 | PFIZER INC. | $3,925 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-28 | Janssen Research & Development, LLC | $10,706 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-07-24 | IRONWOOD PHARMACEUTICALS, INC | $5,740 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-07-24 | IRONWOOD PHARMACEUTICALS, INC | $493 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-07-24 | IRONWOOD PHARMACEUTICALS, INC | $160 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-07-23 | United Therapeutics Corporation | $14,632 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-23 | United Therapeutics Corporation | $3,253 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-07-23 | National Marrow Donor Program | $2,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-07-22 | Boston Scientific Corporation | $1,180 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-07-15 | IRONWOOD PHARMACEUTICALS, INC | $1,200 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-07-15 | IRONWOOD PHARMACEUTICALS, INC | $800 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-07-15 | Eli Lilly and Company | $511 | Research payment | In-kind items and services | EMBER-4: A RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ADJUVANT IMLUNESTRANT VS STANDARD ADJUVANT ENDOCRINE THERAPY IN PATI | 2025 | |
| 2025-07-14 | Medical Device Business Services, Inc. | $36,056 | Research payment | Cash or cash equivalent | VIVIGEN MIS DELIVERY SYSTEM Device, Spine Trauma | Clinical Outcomes Associated with the use of ViviGen in Conjunction with Posterolateral Fusion for the Treatment of Lumb | 2025 |
| 2025-07-10 | PFIZER INC. | $3,081 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-07-09 | United Therapeutics Corporation | $6,372 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-09 | United Therapeutics Corporation | $5,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-09 | United Therapeutics Corporation | $3,000 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-09 | United Therapeutics Corporation | $1,377 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-09 | United Therapeutics Corporation | $200 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Multinational, Phase 3 Study of the Efficacy and Safety of Inhaled Trepr | 2025 |
| 2025-07-08 | United Therapeutics Corporation | $23,148 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | An Open-label Extension Study of Inhaled Treprostinil in Subjects With Idiopathic Pulmonary Fibrosis | 2025 |
| 2025-07-08 | United Therapeutics Corporation | $3,110 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-07-02 | Imperative Care, Inc | $36,765 | Research payment | Cash or cash equivalent | SYMPHONY CATHETER Device, VASCULAR | THE IMPERATIVE TRIAL: TREATMENT OF ACUTE ISCHEMIC STROKE WITH THE ZOOM REPERFUSION SYSTEM | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $160 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $160 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $131 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $131 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $120 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $120 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $75 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $52 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $52 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $50 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $50 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $41 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $41 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $22 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-30 | Ipsen Pharma SAS | $22 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-06-28 | PFIZER INC. | $12,044 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-25 | United Therapeutics Corporation | $5,683 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-06-24 | Boehringer Ingelheim Pharmaceuticals, Inc. | $6,663 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-06-20 | Janssen Research & Development, LLC | $272 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-06-19 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-06-17 | Boston Scientific Corporation | $990 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-06-13 | PFIZER INC. | $6,725 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-06-13 | SI-BONE, INC. | $5,622 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2025 |
| 2025-06-13 | PFIZER INC. | $2,119 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-06-11 | United Therapeutics Corporation | $2,592 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-06-05 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER OPENLABEL STUDY TO ASSESS THE LONGTERM SAFETY AND TOLERABILITY OF RIMEGEPANT FOR THE ACUTE TREATMENT | 2025 |
| 2025-06-04 | Boston Scientific Corporation | $5,000 | Grant | Cash or cash equivalent | General - Structural Heart Device, General - Structural Heart_IC | 2025 | |
| 2025-06-04 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Therapies Device, General - Therapies_EP | 2025 | |
| 2025-06-04 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Therapies Device, General - Therapies_EP | 2025 | |
| 2025-06-04 | Boston Scientific Corporation | $2,000 | Grant | In-kind items and services | General - Therapies Device, General - Therapies_EP | 2025 | |
| 2025-06-01 | Boehringer Ingelheim Pharmaceuticals, Inc. | $24,873 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | An open-label extension trial of the long-term safety and efficacy of BI 1015550 taken orally in patients with idiopathi | 2025 |
| 2025-05-28 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | NURTEC ODT Drug, PAIN | PHASE 3 MULTICENTER RANDOMIZED DOUBLEBLIND GROUP SEQUENTIAL PLACEBOCONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIM | 2025 |
| 2025-05-27 | Boston Scientific Corporation | $1,425 | Research payment | Cash or cash equivalent | Clinical Trial Product Device, Clinical Trial Product_IC | CHAMPION-AF | 2025 |
| 2025-05-27 | PFIZER INC. | $1,050 | Research payment | Cash or cash equivalent | XTANDI Drug, ONCOLOGY | A RANDOMIZED PHASE II TRIAL OF SALVAGE RADIOTHERAPY WITH STANDARD VS ENHANCED ANDROGEN DEPRIVATION THERAPY WITH ENZALUTA | 2025 |
| 2025-05-21 | United Therapeutics Corporation | $9,016 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $147 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-21 | Ipsen Pharma SAS | $51 | Research payment | Cash or cash equivalent | Dysport Drug, Neurology | A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety | 2025 |
| 2025-05-20 | Janssen Research & Development, LLC | $2,992 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-05-12 | PFIZER INC. | $1,500 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAMAX Drug, CARDIOVASCULAR | 2025 | |
| 2025-05-09 | Elekta Limited | $54,250 | Research payment | Cash or cash equivalent | ELEKTA MEDICAL LINEAR ACCELERATOR Device, LINAC SOLUTIONS (LINAC) | Spot-Scanning Proton Arc Therapy | 2025 |
| 2025-05-09 | PFIZER INC. | $5,425 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $4,614 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-07 | United Therapeutics Corporation | $1,468 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-05-06 | PFIZER INC. | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | ELIQUIS Drug, CARDIOVASCULAR;METABOLIC DISEASE | 2025 | |
| 2025-05-01 | IRONWOOD PHARMACEUTICALS, INC | $6,743 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-04-28 | PFIZER INC. | $6,000 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | VYNDAQEL Drug, CARDIOVASCULAR | 2025 | |
| 2025-04-25 | National Marrow Donor Program | $1,530 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | 2025 | ||
| 2025-04-17 | Janssen Research & Development, LLC | $8,432 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-04-17 | IRONWOOD PHARMACEUTICALS, INC | $2,534 | Research payment | Cash or cash equivalent | C3300-201 | 2025 | |
| 2025-04-11 | SI-BONE, INC. | $4,185 | Research payment | Cash or cash equivalent | IFUSE IMPLANT SYSTEM Device, SACROILIAC JOINT DYSFUNCTION | SILVIA | 2025 |
| 2025-04-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | $9,431 | Research payment | Cash or cash equivalent | JASCAYD Drug, RESPIRATORY | A double blind, randomized, placebo-controlled trial evaluating the efficacy and safety of BI 1015550 over at least 52 w | 2025 |
| 2025-04-09 | United Therapeutics Corporation | $864 | Research payment | Cash or cash equivalent | TYVASO Drug, Pulmonary Arterial Hypertension and Pulmonary Hypertension with Interstitial Lung Disease | A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of the Efficacy and Safety of Inhaled Treprostinil in Subj | 2025 |
| 2025-04-09 | Abbott Laboratories | $435 | Long term medical supply or device loan | In-kind items and services | ALINITY M Device, Molecular Diagnostics | 2025 | |
| 2025-04-09 | Abbott Laboratories | $123 | Long term medical supply or device loan | In-kind items and services | ALINITY M Device, Molecular Diagnostics | 2025 | |
| 2025-04-04 | Stryker Corporation | $13,865 | Research payment | Cash or cash equivalent | GAMMA Device, TRAUMA & EXTREMETIES | POST MARKET CLINICAL EVALUATION OF GAMMA 4: PROSPECTIVE, MULTICENTER, FOLLOW-UP STUDY (PEGASUS); CIP#: TA-01-2022 | 2025 |
| 2025-04-03 | Alnylam Pharmaceuticals Inc. | $1,500 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | AMVUTTRA Drug, Genetic Disease | 2025 | |
| 2025-04-01 | PFIZER INC. | $3,450 | Research payment | Cash or cash equivalent | VELSIPITY Drug, INFLAMMATION;PAIN | AN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI | 2025 |
| 2025-04-01 | PFIZER INC. | $1,320 | Research payment | Cash or cash equivalent | VELSIPITY Drug, INFLAMMATION;PAIN | AN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI | 2025 |
| 2025-03-28 | PFIZER INC. | $6,201 | Research payment | Cash or cash equivalent | PREVNAR 20 Biological, VACCINES | A PHASE 4 STUDY USING A TESTNEGATIVE DESIGN TO EVALUATE THE EFFECTIVENESS OF A 20VALENT PNEUMOCOCCAL CONJUGATE VACCINE A | 2025 |
| 2025-03-25 | Janssen Research & Development, LLC | $9,619 | Research payment | Cash or cash equivalent | A Study of Vaccination With 9valent Extraintestinal Pathogenic Escherichia Coli Vaccine ExPEC9V in the Prevention of Inv | 2025 | |
| 2025-03-25 | PFIZER INC. | $3,000 | Research payment | Cash or cash equivalent | VELSIPITY Drug, INFLAMMATION;PAIN | AN OPENLABEL SINGLEARM STUDY TO EVALUATE THE EFFICACY PHARMACOKINETICS AND SAFETY OF ETRASIMOD IN ADOLESCENT SUBJECTS WI | 2025 |
The latest 200 records of 282.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Grosse Pointe, MI, county Wayne County, MI, state Michigan; placed by its city name.
| Measure | Place (city or town) Grosse Pointe, MI | County Wayne County, MI | State Michigan |
|---|---|---|---|
| Population B01003 | 5,541 | 1,772,259 | 10,077,761 |
| Population, 2020 census P1 | 5,678 | 1,793,561 | 10,077,331 |
| Median age B01002 | 43.8 | 37.9 | 40.2 |
| Under 18 B01001 | 26.6% | 23.6% | 21.2% |
| 65 and over B01001 | 23.2% | 16.6% | 18.6% |
| Households B11001 | 2,211 | 700,591 | 4,076,369 |
| Foreign born B05002 | 7.8% | 10.3% | 7.2% |
| Median household income B19013 | $158,853 | $60,539 | $72,875 |
| Median family income B19113 | $180,357 | $79,522 | $93,357 |
| Per capita income B19301 | $86,088 | $34,906 | $40,735 |
| Poverty rate B17001 | 2.8% | 20.8% | 13.2% |
| Unemployment rate B23025 | 4.3% | 8.7% | 5.7% |
| Civilian labor force B23025 | 2,769 | 828,838 | 5,018,449 |
| Mean commute (minutes) B08013 | 24.4 | 24.7 | 24.2 |
| Bachelor's degree or higher B15003 | 73.1% | 27.6% | 32.4% |
| Housing units B25001 | 2,452 | 801,083 | 4,622,236 |
| Owner-occupied B25003 | 85.9% | 64.8% | 73.2% |
| Renters B25003 | 14.1% | 35.2% | 26.8% |
| Median home value B25077 | $436,800 | $178,500 | $231,600 |
| Median gross rent B25064 | $1,725 | $1,132 | $1,129 |
| White, not Hispanic B03002 | 91.0% | 47.9% | 72.4% |
| Black B03002 | 1.5% | 36.6% | 13.1% |
| Hispanic or Latino B03002 | 3.1% | 6.9% | 5.9% |
| Asian B03002 | 1.0% | 3.7% | 3.4% |
| American Indian and Alaska Native B03002 | 0.1% | 0.2% | 0.3% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Grosse Pointe, MI.
Comments